5-氟烟酸乙酯 | 22620-29-7

• 物质功能分类: 医药中间体 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 5-氟烟酸乙酯
• 英文名称: ethyl 5-fluoronicotinate
• 英文别名: 5-Fluor-nicotinsaeure-ethylester；Ethyl-5-fluornicotinat；ethyl 5-fluoropyridine-3-carboxylate
• CAS: 22620-29-7
• 化学式: C₈H₈FNO₂
• 分子量: 169.155
• InChiKey: GAOUAPNRNSFZGW-UHFFFAOYSA-N

物化性质

• 沸点：
  214.0±25.0 °C(Predicted)
• 密度：
  1?+-.0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  39.2
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 安全说明：
  S26,S36/37/39
• 危险类别码：
  R36/37/38
• 海关编码：
  2933399090

反应信息

• 作为反应物：
  描述：

  5-氟烟酸乙酯 在 哌啶 、 吡啶 、 氯甲酸乙酯 、 sodium carbonate 、 一水合肼 作用下， 以 吡啶 、 乙二醇 为溶剂， 反应 2.0h， 生成 N-[3-(5-fluoro-pyridin-3-yl)acryloyl]-4-(4-diphenylmethyl-1-piperazinyl)butylamine
  参考文献：
  名称：

  Acrylamide derivatives as antiallergic agents. 2. Synthesis and structure activity relationships of N-[4-[4-(diphenylmethyl)-1-piperazinyl]butyl]-3-(3-pyridyl)acrylamides

  摘要：

  A new series of 3-(3-pyridyl)acrylamides 16, 17, 19, and 26, and 5-(3-pyridyl)-2,4-pentadienamides 20-25 were prepared and evaluated for their antiallergic activity. Several of these compounds exhibited more potent inhibitory activities than the parent compound 1a [(E)-N-[4-[4-(diphenylmethyl)-1-piperazinyl]butyl]-3- (3-pyridyl)acrylamide] against the rat passive cutaneous anaphylaxis (PCA) reaction and the enzyme 5-lipoxygenase. Particularly, (E)-N-[4-[4-(diphenylmethyl)-1-piperazinyl]butyl]-3- (6-methyl-3-pyridyl)acrylamide (17p) showed an ED50 value of 3.3 mg/kg po in the rat PCA test, which was one-fifth of ketotifen and oxatomide. As compared with ketotifen and oxatomide, compound 17p (AL-3264) possessed a better balance of antiallergic properties due to inhibition of chemical mediator release, inhibition of 5-lipoxygenase, and antagonism of histamine.

  DOI：

  10.1021/jm00123a012

文献信息

• [EN] PHOSPHODIESTERASE 4 INHIBITORS, INCLUDING N-SUBSTITUTED ANILINE AND DIPHENYLAMINE ANALOGS<br/>[FR] INHIBITEURS DE PHOSPHODIESTERASE 4 COMPRENANT DES ANALOGUES DE DIPHENYLAMINE ET D'ANILINE N-SUBSTITUES
  申请人：MEMORY PHARM CORP

  公开号：WO2004009552A1

  公开（公告）日：2004-01-29

  PDE4 inhibition is achieved by novel compounds, e.g., N-substituted aniline and diphenylamine analogs. The compounds of the present invention are of Formula (I): wherein R1, R2 R 3 and R4 are as defined herein.

  PDE4抑制作用是通过新型化合物实现的，例如N-取代苯胺和二苯胺类似物。本发明的化合物为公式(I)：其中R1，R2，R3和R4如本文所述定义。
• [EN] POLYHETEROCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS<br/>[FR] COMPOSES POLYHETEROCYCLIQUES ET UTILISATION DE CEUX-CI COMME ANTAGONISTES DU RECEPTEUR METABOTROPIQUE DU GLUTAMATE
  申请人：ASTRAZENECA AB

  公开号：WO2005080386A1

  公开（公告）日：2005-09-01

  The present invention relates to new compounds of formula (I), wherein P, Q, X1, X2, X3, X4, X5, X6, R1, R2, R3, m, n, and p are as defined as in formula (I), or salts, or hydrates thereof, processes for their preparation and new intermediates used in the preparation thereof, pharmaceutical compositions containing said compounds and to the use of said compounds in therapy.

  本发明涉及公式(I)的新化合物，其中P、Q、X1、X2、X3、X4、X5、X6、R1、R2、R3、m、n和p的定义如公式(I)中所述，或其盐或水合物，以及其制备方法和用于制备的新中间体，含有所述化合物的药物组合物以及所述化合物在治疗中的应用。
• [EN] BENZENE SULFONAMIDES AS CCR9 INHIBITORS<br/>[FR] BENZÈNE-SULFONAMIDES À TITRE D'INHIBITEURS DE CCR9
  申请人：NORGINE BV

  公开号：WO2015097122A1

  公开（公告）日：2015-07-02

  The present invention relates to compounds useful as CCR9 modulators, to compositions containing them, to methods of making them, and to methods of using them. In particular, the present invention relates to compounds capable of modulating the function of the CCR9 receptor by acting as partial agonists, antagonists or inverse agonists. Such compounds may be useful to treat, prevent or ameliorate a disease or condition associated with CCR9 activation, including inflammatory and immune disorder diseases or conditions such as inflammatory bowel diseases (IBD).

  本发明涉及作为CCR9调节剂有用的化合物，包含这些化合物的组合物，制备它们的方法，以及使用它们的方法。具体而言，本发明涉及能够通过作为部分激动剂、拮抗剂或逆激动剂来调节CCR9受体功能的化合物。这些化合物可能有助于治疗、预防或缓解与CCR9激活相关的疾病或状况，包括炎症和免疫性疾病或状况，如炎症性肠病（IBD）。
• Phosphodiesterase 4 inhibitors, including N-substituted aniline and diphenylamine analogs
  申请人：Schumacher A. Richard

  公开号：US20050119225A1

  公开（公告）日：2005-06-02

  PDE4 inhibition is achieved by novel compounds, e.g., N-substituted aniline and diphenylamine analogs. The compounds of the present invention are of Formula I: wherein R 1 , R 2 , R 3 and R 4 are as defined herein.

  PDE4抑制是通过新型化合物实现的，例如，N-取代苯胺和二苯胺类似物。本发明的化合物属于公式I：其中R1，R2，R3和R4如本文所定义。
• .omega.-(3-pyridyl)alkenamide derivatives and anti-allergenic
  申请人：Dainippon Pharmaceutical Co., Ltd.

  公开号：US04778796A1

  公开（公告）日：1988-10-18

  Compounds of the formula: ##STR1## wherein X is alkylene or --(CR.sub.6 .dbd.CR.sub.7).sub.r -- wherein R.sub.6 is H, alkyl or phenyl, R.sub.7 is H, alkyl, cyano or phenyl, and r is 1 or 2; A is alkylene or alkylene interrupted by at least one double bond; R.sub.1 is H, halogen, alkyl, alkoxy, alkylthio, cycloalkyloxy, cycloalkylthio, alkoxycarbonyl, carboxy, phenyl, phenoxy, phenylthio, 3-pyridyloxy or 3-pyridylthio; R.sub.2 is H, hydroxy, alkanoyloxy or alkoxycarbonyloxy, or adjacent R.sub.1 and R.sub.2 may combine to form tetramethylene or --CH.sub.2 OCR.sub.8 R.sub.9 O-- (R.sub.8 and R.sub.9 are alkyl); R.sub.3 is H, alkyl or hydroxyalkyl; R.sub.4 is H or alkyl; R.sub.5 is phenyl, heteroaryl or --(CH.sub.2).sub.m --CHR.sub.10 R.sub.11 (R.sub.10 is H or phenyl, R.sub.11 is phenyl or pyridyl and m is 0 to 2); p is 0 or 1; and q is 2 or 3; the phenyl group or moiety being optionally substituted, and a salt thereof, process for the preparation thereof, and pharmaceutical composition containing the same. Said compounds and salts thereof show excellent antiallergic activity mainly through 5-lipoxygenase inhibiting activity, antihistamine activity and/or inhibitory activity against chemical mediator release and useful for treatment of allergic diseases.

  该公式化合物为：##STR1## 其中X为烷基或--(CR.sub.6.dbd.CR.sub.7).sub.r --，其中R.sub.6为H、烷基或苯基，R.sub.7为H、烷基、氰基或苯基，r为1或2；A为烷基或至少有一个双键的烷基；R.sub.1为H、卤素、烷基、烷氧基、烷硫基、环烷氧基、环烷硫基、烷氧羰基、羧基、苯基、苯氧基、苯硫基、3-吡啶氧基或3-吡啶硫基；R.sub.2为H、羟基、烷酰氧基或烷氧羰酰氧基，或相邻的R.sub.1和R.sub.2可以结合形成四亚甲基或--CH.sub.2 OCR.sub.8 R.sub.9 O--（其中R.sub.8和R.sub.9为烷基）；R.sub.3为H、烷基或羟基烷基；R.sub.4为H或烷基；R.sub.5为苯基、杂环芳基或--(CH.sub.2).sub.m --CHR.sub.10 R.sub.11（其中R.sub.10为H或苯基，R.sub.11为苯基或吡啶基，m为0到2）；p为0或1；q为2或3；苯基或基团可选择性地被取代；以及其盐、制备方法和含有它的药物组成物。所述化合物及其盐主要通过5-脂氧酶抑制活性、抗组胺活性和/或化学介质释放抑制活性表现出优异的抗过敏活性，并用于治疗过敏性疾病。